Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer

PURPOSE: The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1% to 2% of non–small-cell lung cancers (NSCLCs), which confer sensitivity to treatment with the anaplastic lymphoma kinase (ALK)/ROS1/mesenchymal-epithelial transition factor inhibitor crizotinib. Currently, insights...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Gainor, Justin F., Tseng, Diane, Yoda, Satoshi, Dagogo-Jack, Ibiayi, Friboulet, Luc, Lin, Jessica J., Hubbeling, Harper G., Dardaei, Leila, Farago, Anna F., Schultz, Katherine R., Ferris, Lorin A., Piotrowska, Zofia, Hardwick, James, Huang, Donghui, Mino-Kenudson, Mari, Iafrate, A. John, Hata, Aaron N., Yeap, Beow Y., Shaw, Alice T.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5766287/
https://ncbi.nlm.nih.gov/pubmed/29333528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.17.00063
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados